The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBritish American Tobacco Regulatory News (BATS)

Share Price Information for British American Tobacco (BATS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2,335.00
Bid: 2,334.00
Ask: 2,336.00
Change: -16.00 (-0.68%)
Spread: 2.00 (0.086%)
Open: 2,346.00
High: 2,347.00
Low: 2,334.00
Prev. Close: 2,351.00
BATS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Russia business update - sale completed

14 Sep 2023 09:00

RNS Number : 3751M
British American Tobacco PLC
14 September 2023
 

British American Tobacco p.l.c.

14 September 2023

 

 

Russia business update - sale completed

Further to our announcement on 7 September 2023, we have now completed the sale of our Russian and Belarusian businesses. The sale has been carried out in compliance with local and international laws and follows the receipt of all necessary approvals.

 

ENDSEnquiries

Media Centre+44 (0) 20 7845 2888 (24 hours) | @BATplc

Investor RelationsVictoria Buxton: +44 (0)20 7845 2012Amy Chamberlain +44 (0)20 7845 1124John Harney: +44 (0)20 7845 1263

Jane Henderson +44 (0)207845 1117

 About BAT

BAT is a leading, multi-category consumer goods business with a purpose to build A Better Tomorrow™ by reducing the health impact of its business through offering a greater choice of enjoyable and less risky products for adult consumers.

The company continues to be clear that combustible cigarettes pose serious health risks, and the only way to avoid these risks is not to start or to quit. BAT encourages those who would otherwise continue to smoke to switch completely to scientifically-substantiated, reduced-risk alternatives*†. In order to deliver this, BAT is transforming into a truly consumer-centric multi-category consumer products business.

BAT's ambition is to have 50 million consumers of its non-combustible products by 2030 and to generate £5billion of New Categories revenue by 2025. BAT has set stretching ESG targets including achieving carbon neutrality for Scopes 1 & 2 by 2030 and eliminating unnecessary single-use plastic and making all plastic packaging reusable, recyclable or compostable by 2025.

BAT employs over 50,000 people. The BAT Group generated revenue of £27.65 billion in 2022 and profit from operations of £10.5 billion.

The company's Strategic Portfolio is made up of its global cigarette brands and a growing range of reduced-risk*† New Category tobacco and nicotine products and traditional non-combustible tobacco products. These include vapour, tobacco heating products, modern oral products including tobacco-free nicotine pouches, as well as traditional oral products such as snus and moist snuff. In the first half of 2023, we had 24 million consumers of our non-combustible products, a rise of 1.5 million on full year 2022.

* Based on the weight of evidence and assuming a complete switch from cigarette smoking. These products are not risk free and are addictive.

† Our vapour product Vuse (including Alto, Solo, Ciro and Vibe), and certain products, including Velo, Grizzly, Kodiak, and Camel Snus, which are sold in the U.S., are subject to FDA regulation and no reduced-risk claims will be made as to these products without agency clearance.

 

Forward-looking statements

This release contains certain forward-looking statements, including "forward-looking" statements made within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made through the use of words or phrases such as "believe," "anticipate," "could," "may," "would," "should," "intend," "plan," "potential," "predict," "will," "expect," "estimate," "project," "positioned," "strategy," "outlook", "target" and similar expressions. These include statements regarding our customer target ambition, New Categories revenue targets and our ESG targets.

All such forward-looking statements involve estimates and assumptions that are subject to risks, uncertainties and other factors. It is believed that the expectations reflected in this release are reasonable but they may be affected by a wide range of variables that could cause actual results to differ materially from those currently anticipated. A review of the reasons why actual results and developments may differ materially from the expectations disclosed or implied within forward-looking statements can be found by referring to the information contained under the headings "Cautionary Statement" and "Group Principal Risks " in the 2022 Annual Report and Form 20-F of British American Tobacco p.l.c. (BAT). 

Additional information concerning these and other factors can be found in BAT's filings with the U.S. Securities and Exchange Commission ("SEC"), including the Annual Report on Form 20-F and Current Reports on Form 6-K, which may be obtained free of charge at the SEC's website, http://www.sec.gov and BAT's Annual Reports, which may be obtained free of charge from the BAT website www.bat.com.

Past performance is no guide to future performance and persons needing advice should consult an independent financial adviser. The forward-looking statements reflect knowledge and information available at the date of preparation of this release and BAT undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. Readers are cautioned not to place undue reliance on such forward-looking statements.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDEAXNDFLNDEFA
Date   Source Headline
1st May 20247:05 amRNSTransaction in Own Shares
1st May 20247:00 amRNSShare Buyback – Non-Discretionary Agreement
30th Apr 20247:00 amRNSTransaction in Own Shares
29th Apr 20245:42 pmRNSTender Offer Pricing
29th Apr 202412:40 pmRNSResult of Tender Offer
29th Apr 20247:00 amRNSTransaction in Own Shares
26th Apr 20247:00 amRNSTransaction in Own Shares
25th Apr 20247:00 amRNSTransaction in Own Shares
24th Apr 20244:00 pmRNSResult of AGM
24th Apr 202411:45 amRNSAGM Statement
24th Apr 20247:00 amRNSTransaction in Own Shares
23rd Apr 20247:00 amRNSTransaction in Own Shares
22nd Apr 20247:00 amRNSTransaction in Own Shares
19th Apr 20247:00 amRNSTransaction in Own Shares
18th Apr 20247:00 amRNSTransaction in Own Shares
17th Apr 202410:10 amRNSDirector/PDMR Shareholding
17th Apr 202410:05 amRNSDirector/PDMR Shareholding
15th Apr 202411:55 amRNSTender Offer
15th Apr 20247:00 amRNSTransaction in Own Shares
12th Apr 20247:00 amRNSTransaction in Own Shares
11th Apr 20247:00 amRNSTransaction in Own Shares
10th Apr 20246:00 pmRNSPublication of Final Terms
10th Apr 20247:00 amRNSTransaction in Own Shares
9th Apr 202411:10 amRNSPublication of Suppl.Prospcts
9th Apr 20247:00 amRNSTransaction in Own Shares
8th Apr 20244:00 pmRNSDirector/PDMR Shareholding
8th Apr 20247:00 amRNSTransaction in Own Shares
5th Apr 20242:10 pmRNSDirector/PDMR Shareholding
5th Apr 20242:05 pmRNSDirector/PDMR Shareholding
5th Apr 20242:00 pmRNSDirector/PDMR Shareholding
5th Apr 20247:00 amRNSTransaction in Own Shares
4th Apr 20243:30 pmRNSDirector/PDMR Shareholding
4th Apr 20242:40 pmRNSDirector Declaration
4th Apr 20247:00 amRNSTransaction in Own Shares
3rd Apr 20242:00 pmRNSDirector/PDMR Shareholding
3rd Apr 20247:00 amRNSTransaction in Own Shares
2nd Apr 202410:30 amRNSTotal Voting Rights
2nd Apr 20247:00 amRNSTransaction in Own Shares
28th Mar 202410:15 amRNSPublication of Suppl.Prospcts
28th Mar 20247:00 amRNSTransaction in Own Shares
27th Mar 20247:00 amRNSTransaction in Own Shares
26th Mar 20247:00 amRNSTransaction in Own Shares
25th Mar 20247:00 amRNSTransaction in Own Shares
22nd Mar 202410:40 amRNSDirector/PDMR Shareholding
22nd Mar 202410:35 amRNSDirector/PDMR Shareholding
22nd Mar 202410:30 amRNSDirector/PDMR Shareholding
22nd Mar 20247:00 amRNSTransaction in Own Shares
21st Mar 20243:26 pmRNSDirector/PDMR Shareholding
21st Mar 20243:20 pmRNSDirector/PDMR Shareholding
21st Mar 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.